Meta-analysis of 31 studies (over 700 patients with solid tumours and pre-existing rheumatologic disease) on immune checkpoint inhibitors: pooled flare incidence was 33.8% (grade 3-5: 4.2%), median onset 38.5 days, varying from 3.8% in SLE to 46.4% in psoriatic arthritis.
Meta-analysisn = 31 studies
Yamada et al. Flare incidences of pre-existing rheumatologic diseases in patients with solid tumors receiving immune checkpoint inhibitors: A systematic review and meta-analysis